146 related articles for article (PubMed ID: 37530954)
1. Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Di Fusco M; Keshishian A; Delinger R; Ferri M; Jiang J; Seigel L; Yuce H; Guo JD
J Thromb Thrombolysis; 2023 Nov; 56(4):626-634. PubMed ID: 37530954
[TBL] [Abstract][Full Text] [Related]
2. Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA.
Dhamane AD; Hernandez I; Di Fusco M; Gutierrez C; Ferri M; Russ C; Tsai WL; Emir B; Yuce H; Keshishian A
Am J Cardiovasc Drugs; 2022 May; 22(3):333-343. PubMed ID: 34671944
[TBL] [Abstract][Full Text] [Related]
3. Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Deitelzweig S; Keshishian A; Kang A; Jenkins A; Atreja N; Schuler P; Jiang J; Yuce H; Sun X; Lip GYH
Eur J Intern Med; 2023 Feb; 108():37-42. PubMed ID: 36456387
[TBL] [Abstract][Full Text] [Related]
4. Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Guo JD; Keshishian A; Delinger R; Russ C; Rosenblatt L; Jiang J; Yuce H; Ferri M
J Thromb Thrombolysis; 2024 Jan; 57(1):1-10. PubMed ID: 37530955
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
J Manag Care Spec Pharm; 2018 Sep; 24(9):911-920. PubMed ID: 30156450
[TBL] [Abstract][Full Text] [Related]
6. The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.
Sussman M; Di Fusco M; Tao CY; Guo JD; Gillespie JA; Ferri M; Adair N; Cato MS; Shirkhorshidian I; Barnes GD
J Med Econ; 2021; 24(1):1070-1082. PubMed ID: 34415229
[TBL] [Abstract][Full Text] [Related]
7. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.
Willey V; Franchino-Elder J; Fu AC; Wang C; Sander S; Tan H; Kraft E; Jain R
BMJ Open; 2018 Jun; 8(6):e020676. PubMed ID: 29961012
[TBL] [Abstract][Full Text] [Related]
8. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
[TBL] [Abstract][Full Text] [Related]
10. Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
Kaatz S; Coleman CI; Bookhart B; Laliberté F; Nelson WW; Brown K; Martin S; Schein J; Lefebvre P
Curr Med Res Opin; 2018 Feb; 34(2):275-284. PubMed ID: 29164990
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
[TBL] [Abstract][Full Text] [Related]
12. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study.
Lip GYH; Keshishian AV; Kang AL; Dhamane AD; Luo X; Li X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig S
J Intern Med; 2021 Jan; 289(1):42-52. PubMed ID: 32602228
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
[TBL] [Abstract][Full Text] [Related]
14. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.
Munir MB; Hlavacek P; Keshishian A; Guo JD; Mallampati R; Ferri M; Russ C; Emir B; Cato M; Yuce H; Hsu JC
PLoS One; 2022; 17(2):e0263903. PubMed ID: 35176074
[TBL] [Abstract][Full Text] [Related]
15. Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
Ajabnoor AM; Zghebi SS; Parisi R; Ashcroft DM; Rutter MK; Doran T; Carr MJ; Mamas MA; Kontopantelis E
PLoS Med; 2022 Jun; 19(6):e1004003. PubMed ID: 35671329
[TBL] [Abstract][Full Text] [Related]
16. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
18. A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Nadkarni A; Vo L
J Manag Care Spec Pharm; 2020 May; 26(5):639-651. PubMed ID: 32347184
[TBL] [Abstract][Full Text] [Related]
19. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
20. Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands.
Chen Q; Toorop MMA; Tops LF; Lijfering WM; Cannegieter SC
JAMA Netw Open; 2023 Apr; 6(4):e239973. PubMed ID: 37097630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
